Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CTS-1027 in Hepatitis C
NCT00570336Phase 2Completed
- Sponsor
- Conatus Pharmaceuticals Inc.
- Start
- Dec 2007
- Primary completion
- Jul 2009
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of CTS-1027 in hepatitis C (HCV) (5 arms), sponsored by Conatus Pharmaceuticals Inc. Primary endpoints: Number of adverse events at each dose level at 24 weeks and Alanine aminotransferase (ALT) and Aspartate aminotransferase (AST) levels at each dose at 24 weeks. Started Dec 2007; status: completed.
02
Drugs
CTS-1027
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT00570336.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00570336.